PMS37 Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan
No Thumbnail Available
Date
2014-11-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Value in Health
Abstract
The purpose of present study was to evaluate the cost-effectiveness of tocilizumab (TCZ) vs. infliximab (IFX) for the treatment of patients with rheumatoid arthritis (RA) from the perspective of Ministry of Health (MoH) over a patient lifetime horizon in Kazakhstan.
Description
Keywords
Citation
C. Bektur, F. Kayir, T. Nurgozhin, PMS37 - Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Page A379